William Sargent has over 30 years in the pharmaceutical industry, preceded by 10 years as an independent researcher in academia.
He is well versed in the therapeutic development emerging from local universities, having served as member of the Chicago Innovation Mentors (CIM) program since 2013. Previously, he held senior positions at Pfizer, Hoechst-Roussell Pharmaceuticals, Lorex Pharmaceuticals, Searle, and Pharmacia. As President and General Manager of Lorex, he oversaw FDA approval for direct-to-consumer advertising for the lead product Ambien®. At Pfizer, he led the International launch of Sutent® for renal cell carcinoma and gastrointestinal stromal cancer as Senior Medical Director and Team Leader for the anti-angiogenic portfolio.
Bill received a PhD in physiology from the University of Tennessee Center for the Health Sciences where he served as faculty in Physiology and Biophysics for approximately 10 years.